Arvinas to Participate in Upcoming Investor Conferences
Arvinas (Nasdaq: ARVN) said management will participate in four investor conferences in early March 2026, including TD Cowen, Leerink Global Healthcare, Barclays Global Healthcare, and Jefferies Biotech on the Beach.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Arvinas (Nasdaq: ARVN) said management will participate in four investor conferences in early March 2026, including TD Cowen, Leerink Global Healthcare, Barclays Global Healthcare, and Jefferies Biotech on the Beach.
Each appearance is a fireside chat with specific times on March 3, 9, 10 and 11; replays will be posted in the Events and Presentations section of the company website.
Details
News Market Reaction – ARVN
On Feb 23, the day this news came out, ARVN closed 2.59% above the previous close.
Data tracked by StockTitan Argus for the Feb 23 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HAVEN, Conn, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in four upcoming investor conferences:
- TD Cowen 46th Annual Health Care Conference on Tuesday, March 3. Management will participate in a fireside chat, available here, at 1:10 p.m. ET.
- Leerink Global Healthcare Conference on Monday, March 9. Management will participate in a fireside chat, available here, at 4:20 p.m. ET.
- Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10. Management will participate in a fireside chat, available here, at 11:00 a.m. ET.
- 2026 Jefferies Biotech on the Beach Summit on Wednesday, March 11.
Replays of the fireside chats will be available on the Events and Presentations section of the Company’s website.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including ARV-102, targeting LRRK2 for neurodegenerative disorders; ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.